文章：

脐带血移植治疗癌症

Umbilical-cord blood transplantation for the treatment of cancer

原文发布日期：2003-07-01

DOI: 10.1038/nrc1125

类型: Review Article

开放获取: 否

要点：

1. Allogeneic bone-marrow transplantation is the best treatment for patients with haematological cancers. This procedure, however, is limited by lack of suitable donors, as well as the complications of graft-versus-host disease (GVHD) and opportunistic infection.
2. Umbilical-cord blood is an excellent source of haematopoietic stem cells. It has the advantages of speedy availability and reduced incidence of causing GVHD. This allows for transplantation of grafts with limited HLA disparity, and thereby extends the donor pool.
3. The main determinants of successful umbilical-cord blood transplant are the number of cells that are available for transplantation and HLA matching.
4. Cord blood transplantation has been validated as an alternative to bone-marrow transplantation for the treatment of leukaemia in children.
5. A number of approaches are being developed to improve the efficacy of cord blood transplantation in adults, such as multiple-unit transplantation and reduced intensity of chemo-radiation therapy.

要点翻译：

1. 异基因骨髓移植是血液恶性肿瘤患者的最佳治疗方法。然而，该疗法因缺乏合适供体、以及移植物抗宿主病和机会性感染等并发症而受到限制。
2. 脐带血是造血干细胞的优质来源，具有获取迅速和降低移植物抗宿主病发生率的优势。这使得人类白细胞抗原存在有限不匹配的移植物能够进行移植，从而扩展了供体库。
3. 成功进行脐带血移植的主要决定因素是可用的细胞数量及人类白细胞抗原匹配度。
4. 脐带血移植已被证实可作为骨髓移植的替代方案用于儿童白血病的治疗。
5. 目前正在开发多种方法以提高脐带血移植在成人中的疗效，例如多单位移植和降低放化疗强度。

英文摘要：

Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited by the lack of suitable bone-marrow donors, the risk of graft-versus-host disease (GVHD) and slow immune reconstitution. Umbilical-cord blood is an alternative source of haematopoietic stem cells that has recently been tested in both child and adult cancer patients. These studies have identified several advantages to umbilical-cord cell transplantation, including a lower incidence of GVHD. Umbilical-cord blood is therefore a promising alternative to bone-marrow-derived stem cells.

摘要翻译： 

造血干细胞移植用于治疗多种血液系统恶性肿瘤，但受限于合适的骨髓供体短缺、移植物抗宿主病（GVHD）风险以及免疫重建缓慢。脐带血是造血干细胞的替代来源，近期已在儿童及成人癌症患者中开展研究。这些研究证实脐带血细胞移植具有多项优势，包括GVHD发生率较低。因此，脐带血有望成为骨髓来源干细胞的有前景的替代选择。

原文链接：

Umbilical-cord blood transplantation for the treatment of cancer